PlushCare Review
We track PlushCare but publish no price for it, and this page explains exactly why.
PlushCare does not publish a tirzepatide price we can interpret and verify from its own material, so we publish none. A figure copied from a third-party round-up without a capture date is not a price, it is a rumour with a dollar sign.
That is not an accusation. Programmes price behind an intake for ordinary commercial reasons. But a comparison site exists to make cost visible before you commit, and a programme that reveals cost only after you have handed over contact details and a health history has opted out of that comparison.
PlushCare operates a primary-care membership that can bill insurance for visits and sends prescriptions to a retail pharmacy. The medication price is whatever your pharmacy and plan produce, so no programme rate exists for us to publish.
Source
Tracked entity; no verified GLP-1 medication price as of 2026-08-05
Of the 32 programmes on this site, 11 have a price we read at the provider or manufacturer, 6 carry a third-party figure we have not confirmed, and 15 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
First-year all-in cost
What to ask PlushCare before you give them anything
- What is the total monthly cost at a 10 mg maintenance dose, including every fee?
- Does that figure change as the dose escalates?
- Is there a membership, consultation, shipping or laboratory charge on top?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What notice is required to cancel, and what is refundable before shipment?
Answers to those six in writing amount to published pricing, and we will record them here with the date. Send them through contact.
Why a missing price is itself information
A programme that publishes a price is making a claim it can be held to. A programme that reveals cost only after an intake has made a commercial choice: it wants contact details and a medical history before you can compare it against anything. That is legal and common, and worth noticing.
It also makes an honest comparison impossible. Every figure on this site is stated all-in at a named dose, and there is no way to place PlushCare on that axis without a number from PlushCare.
What the alternatives publish
The cheapest tracked route, NexLife, publishes $215 a month all-in at a 10 mg maintenance dose and about $2,580 for a first year. Several publish a full ladder from the starter dose to the ceiling. Those figures can be checked against the provider's own page in under a minute, which is the standard PlushCare is being measured against.
What we will not do
Estimate. Several comparison sites carry figures for programmes that publish none, generally by copying an older round-up that copied an earlier one. That is how a promotional rate from two years ago becomes a current price, and it is the most common error in this category.
A blank row is less useful than a number and considerably more honest than a wrong one.
Programmes that do publish a price
Every other programme in our directory states a figure we could capture at at least one dose tier. The cheapest verified all-in cost at a maintenance dose is $215 a month.
How the price behaves as your dose climbs
PlushCare starts at — and rises with your prescription, reaching — at 10 mg. The advertised figure therefore describes roughly four weeks of a twelve-month course. Budget from the 10 mg row, because that is where most of your year happens.
Dose-scaled pricing is not misconduct — more active drug does cost a compounder more. But it means your bill rises exactly as the dose starts working, which inverts the incentive you face and is invisible in any table quoting one number.
What a longer horizon costs here
Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.
| If you maintain at | Per month | One year | Three years |
|---|
Commitment, refunds and what is at risk
No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.
Cancellation: not published. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.
What this programme does not publish
Measured against our published criteria, PlushCare does not publish: price published at every dose tier; price does not rise as the dose escalates; dispensing pharmacy or prescriber named before purchase; prepaid term and its rate published; cancellation terms published. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.
Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.
Seven questions before you enrol
- What is the total in month six at 10 mg, including every fee?
- Which compounding pharmacy fills the prescription, by name and state licence?
- Is the prescribing clinician licensed in my state?
- What is the vial concentration and the beyond-use date?
- Does the quoted rate hold at renewal, or revert?
- What happens if a shipment arrives warm, and who pays for the replacement?
- What notice is required to cancel, and what is refundable before shipment?
None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.
Using it well if you do enrol
Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.
Putting plushcare in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting any one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 17 programmes publish a price we could capture, spanning $215 to $548 a month all-in at a maintenance dose. Against a spread that wide, most optimisation attempted at the margins is worth less than getting the basis right once.
What good looks like
A programme that states a figure at a named dose, names the pharmacy behind it, publishes cancellation terms before payment, and says plainly that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority of the market does all four.
The cheapest verified route sits at $215 a month all-in, which establishes that disclosure and low price are not in tension. Programmes publishing more are not systematically dearer — which undercuts the usual explanation for withholding.
What to do next
Narrow to two or three on the criterion that actually binds for you, open the individual reviews, and send each the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel, and what is refundable.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.